Lantheus Holdings, Inc. to Post FY2025 Earnings of $5.71 Per Share, William Blair Forecasts (NASDAQ:LNTH)

Lantheus Holdings, Inc. (NASDAQ:LNTH) – Stock analysts at William Blair issued their FY2025 earnings per share (EPS) estimates for shares of Lantheus in a research report issued to clients and investors on Tuesday, July 2nd. William Blair analyst A. Hsieh forecasts that the medical equipment provider will post earnings per share of $5.71 for the year. The consensus estimate for Lantheus’ current full-year earnings is $6.46 per share. William Blair also issued estimates for Lantheus’ Q4 2025 earnings at $1.44 EPS.

LNTH has been the subject of a number of other reports. B. Riley raised their price target on Lantheus from $95.00 to $99.00 and gave the stock a “buy” rating in a research note on Thursday, April 18th. Truist Financial raised their price target on Lantheus from $82.00 to $96.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Mizuho raised their price target on Lantheus from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Friday, May 3rd. Finally, StockNews.com downgraded Lantheus from a “buy” rating to a “hold” rating in a research note on Friday, May 3rd. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat.com, Lantheus has a consensus rating of “Moderate Buy” and a consensus price target of $99.17.

Lantheus Trading Up 1.4 %

Shares of NASDAQ LNTH opened at $79.56 on Thursday. Lantheus has a one year low of $50.20 and a one year high of $91.81. The firm has a market capitalization of $5.51 billion, a PE ratio of 12.15 and a beta of 0.51. The company has a current ratio of 4.84, a quick ratio of 4.55 and a debt-to-equity ratio of 0.59. The business has a 50-day moving average price of $78.32 and a two-hundred day moving average price of $66.06.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.51 EPS for the quarter, topping analysts’ consensus estimates of $1.40 by $0.11. Lantheus had a return on equity of 54.10% and a net margin of 33.72%. The firm had revenue of $369.98 million during the quarter, compared to analyst estimates of $349.46 million.

Insider Activity at Lantheus

In related news, CAO Andrea Sabens sold 341 shares of the firm’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the transaction, the chief accounting officer now directly owns 62,898 shares of the company’s stock, valued at approximately $4,836,227.22. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In other Lantheus news, Director Heinz Christoph Maeusli sold 18,373 shares of Lantheus stock in a transaction that occurred on Tuesday, May 28th. The stock was sold at an average price of $79.19, for a total value of $1,454,957.87. Following the transaction, the director now directly owns 23,340 shares of the company’s stock, valued at approximately $1,848,294.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CAO Andrea Sabens sold 341 shares of Lantheus stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $76.89, for a total value of $26,219.49. Following the completion of the transaction, the chief accounting officer now directly owns 62,898 shares in the company, valued at $4,836,227.22. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 32,269 shares of company stock valued at $2,557,300. Corporate insiders own 2.10% of the company’s stock.

Institutional Trading of Lantheus

Several institutional investors have recently modified their holdings of LNTH. UMB Bank n.a. grew its holdings in shares of Lantheus by 161.4% during the 1st quarter. UMB Bank n.a. now owns 400 shares of the medical equipment provider’s stock worth $25,000 after purchasing an additional 247 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Lantheus by 184.1% during the 2nd quarter. GAMMA Investing LLC now owns 321 shares of the medical equipment provider’s stock worth $26,000 after purchasing an additional 208 shares in the last quarter. Tucker Asset Management LLC grew its holdings in shares of Lantheus by 239.0% during the 3rd quarter. Tucker Asset Management LLC now owns 400 shares of the medical equipment provider’s stock worth $28,000 after purchasing an additional 282 shares in the last quarter. Principal Securities Inc. acquired a new stake in shares of Lantheus during the 4th quarter worth approximately $28,000. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of Lantheus during the 1st quarter worth approximately $34,000. Institutional investors and hedge funds own 99.06% of the company’s stock.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.